Publication:
Active study: undetected prevalence and clinical inertia in the treatment of breakthrough cancer pain (BTcP).

dc.contributor.authorCamps-Herrero, C
dc.contributor.authorReina-Zoilo, J J
dc.contributor.authorMonge-Martin, D
dc.contributor.authorCaballero-Martinez, F
dc.contributor.authorGuillem-Porta, V
dc.contributor.authorAranda-Aguilar, E
dc.contributor.authorCarrato-Mena, A
dc.contributor.authorDiaz-Rubio Garcia, E
dc.contributor.authorGarcia-Foncillas Lopez, J
dc.contributor.authorFeijoo-Saus, M
dc.contributor.authorLopez-Lopez, R
dc.contributor.funderECO Foundation
dc.date.accessioned2023-01-25T10:21:20Z
dc.date.available2023-01-25T10:21:20Z
dc.date.issued2018-08-09
dc.description.abstractTo prove if there is clinical inertia in the identification and treatment of episodes of breakthrough cancer pain (BTcP), comparing actual results from clinical practice with clinical oncologists' prior perception. Observational and descriptive study, using information collected by practising medical oncologists, at three moments: (a) questionnaire regarding their professional judgement of the handling of patients with BTcP in their practice, (b) cross-sectional clinical screening, to detect possible existing cases of BTcP in a representative sample of their patients, (c) retrospective self-audit of clinical case histories of patients diagnosed with BTcP to find out about how it has been handled. A random sample on a state level of 108 specialists in medical oncology. 540 patients who suffer some type of cancer pain on the designated study date for each specialist (July-December 2016). The global prevalence of BTcP in the study sample covered 91.3% of the patients who were suffering some type of cancer pain. Barely 2% of the doctors surveyed suspected figures around this mark. 40.9% of the cases had not been previously detected as BTcP by their doctors. Although 90% of the patients who had previously been diagnosed with BTcP received a specific analgesic treatment for the symptoms, 42% of those patients with known BTcP were not able to control their episodes of pain. Clinical inertia is a serious problem in the handling of BTcP in medical oncology services, where it is the subject of a significantly low level of detection and treatment, despite the contrasting perception of specialists.
dc.description.versionSi
dc.identifier.citationCamps Herrero C, Reina Zoilo JJ, Monge Martín D, Caballero Martínez F, Guillem Porta V, Aranda Aguilar E, et al. Active study: undetected prevalence and clinical inertia in the treatment of breakthrough cancer pain (BTcP). Clin Transl Oncol. 2019 Mar;21(3):380-390
dc.identifier.doi10.1007/s12094-018-1925-1
dc.identifier.essn1699-3055
dc.identifier.pmid30094793
dc.identifier.unpaywallURLhttp://ddfv.ufv.es/bitstream/10641/2238/1/Manuscript%20ACTIVE%20Study_def%20%281%29.pdf
dc.identifier.urihttp://hdl.handle.net/10668/12819
dc.issue.number3
dc.journal.titleClinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico
dc.journal.titleabbreviationClin Transl Oncol
dc.language.isoen
dc.organizationHospital Universitario Reina Sofía
dc.organizationHospital Universitario Virgen Macarena
dc.page.number380-390
dc.provenanceRealizada la curación de contenido 04/06/2025
dc.publisherSpringer
dc.pubmedtypeJournal Article
dc.pubmedtypeObservational Study
dc.relation.publisherversionhttps://dx.doi.org/10.1007/s12094-018-1925-1
dc.rights.accessRightsRestricted Access
dc.subjectBreakthrough cancer pain (BTcP)
dc.subjectClinical inertia
dc.subjectPrevalence of BTcP
dc.subject.decsDolor en cáncer
dc.subject.decsPercepción
dc.subject.decsOncología médica
dc.subject.decsAnalgésicos
dc.subject.decsTamizaje masivo
dc.subject.meshAged
dc.subject.meshBreakthrough Pain
dc.subject.meshCancer Pain
dc.subject.meshFemale
dc.subject.meshHumans
dc.subject.meshMale
dc.subject.meshMedical Oncology
dc.subject.meshMiddle Aged
dc.subject.meshPrevalence
dc.subject.meshSurveys and Questionnaires
dc.titleActive study: undetected prevalence and clinical inertia in the treatment of breakthrough cancer pain (BTcP).
dc.typeresearch article
dc.type.hasVersionSMUR
dc.volume.number21
dspace.entity.typePublication

Files

Original bundle

Now showing 1 - 1 of 1
No Thumbnail Available
Name:
RISalud_Accesorestringido.pdf
Size:
93.39 KB
Format:
Adobe Portable Document Format